Abstract 6109
Background
Brachytherapy unit of the Catalan Institute of Oncology (ICO) is a referral centre on Brachytherapy treatments for Catalonia. A total of 700 treatments are performed per year, mainly in gynaecological, prostate and breast cancer. For the last 5 years, intraoperative brachytherapy has been promoted to be done in other centres, outside in the region. That implies that specialist professionals from our cancer centre go to operating rooms in different hospitals. The surgery process is done outside in the Paediatric hospital and the Brachytherapy treatment is realised in the cancer centre ICO. Aim: to describe nursing activities and roles to facilitate the Brachytherapy treatment done outside and in collaboration with other hospitals.
Methods
Descriptive study on cases done last year 2018 with patients outside ICO, most common type of treatments were sarcoma in paediatric tumours, patients with recurrence disease undergoing salvage after surgery or recurrence for breast cancer. Procedure: When a case arrived to the specialist they confirm indication and initiate the process; On the day of surgery, a medical and nurses team from the brachytherapy unit moves to hospital They perform the placement of internal applicators at the time of surgery. Later next 12-24h patient moves to brachytherapy unit to undergo the protocol of radiation. Once the brachytherapy treatment is finished, patient is discharged. The nursing staff of brachytherapy unit takes charge of plan care during treatment.
Results
Pediatric brachytherapy in oncological patient: experience of collaboration of 5 years with 10 patients treated. A total of 53 breast brachytherapy has been done intraoperative: consolidated collaboration, generates around 3 monthly patients from different medical centers. A total of 10 cases done for salvage brachytherapy in patients with recurrence after surgery.
Conclusions
Intraoperative brachytherapy improves the patient’s accessibility to highly specialized treatments. The procedure and development of this treatment in different hospitals improves results in some tumours, reduces the overall time of treatment. Nursing staff has knowledge and skills for the management and care of this patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract